Dupilumab for atopic dermatitis treatment: A single-center retrospective study

---

Atıf İçin Kopyala

YAŞAR SUBAŞI G., BİLGİÇ A., YILMAZ E.

TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, cilt.56, sa.1, ss.12-16, 2022 (ESCI)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 56 Sayı: 1
• Basım Tarihi: 2022
• Doi Numarası: 10.4274/turkderm.galenos.2021.36604
• Dergi Adı: TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY
• Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
• Sayfa Sayıları: ss.12-16
• Anahtar Kelimeler: Atopic dermatitis, dupilumab, treatment, 2-PHASE 3 TRIALS, PLACEBO, MANAGEMENT, ADULTS
• Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
• Akdeniz Üniversitesi Adresli: Evet

Özet

Background and Design: Atopic dermatitis (AD) is a common chronic, recurrent, and itchy inflammatory skin disease. Various therapeutic agents are available, but severe side effects may limit their usage. Recently, dupilumab, a human monoclonal antibody that targets the interleukin-4 (IL-4) receptor alpha subunit of heterodimeric IL-4 and IL-13 receptors, is approved and might be used in patients with resistant AD, with the permission of the Ministry of Health.